Insight Molecular Diagnostics Inc.
جودة البيانات: 100%
IMDX
NASDAQ
Manufacturing
Chemicals
KWD 3.08
▼
KWD 0.09
(-2.84%)
القيمة السوقية: 99.40 M
السعر
KWD 3.09
القيمة السوقية
99.40 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue declined -14.89% annually over 5 years
Negative free cash flow of -25.37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 130.47%
Capital intensive — 78.55% of revenue goes to capex
النمو
Revenue Growth (5Y)
-14.89%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)115.58%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
N/A
ROIC-100.79%
Net Margin-1238.52%
Op. Margin-1260.76%
الأمان
Debt / Equity
N/A
Current Ratio2.79
Interest Coverage-469.03
التقييم
PE (TTM)
-1.98
أقل من متوسط القطاع (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -2.0 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -54.0 |
| Net Margin % | -1238.5 | -41.5 |
| Rev Growth 5Y % | -14.9 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
3 محللين
Buy
الحالي
KWD 3.08
المستهدف
KWD 8.33
KWD 4.00
KWD 9.00
KWD 12.00
التوقعات
ربحية السهم المستقبلية
-KWD 0.87
الإيرادات المقدّرة
8.17 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 0.87
-KWD 0.96 – -KWD 0.79
|
8.17 M | 4 |
| FY2026 |
-KWD 0.75
-KWD 1.03 – -KWD 0.21
|
2.58 M | 4 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.25
-KWD 0.26 – -KWD 0.23
|
475,000.0 | 4 |
| 2026 Q1 |
-KWD 0.26
-KWD 0.31 – -KWD 0.24
|
227,500.0 | 4 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.24 | -KWD 0.72 | -203.2% |
| Q32025 | -KWD 0.24 | -KWD 0.23 | +2.8% |
| Q22025 | -KWD 0.24 | -KWD 0.30 | -25.0% |
| Q12025 | -KWD 0.25 | -KWD 0.23 | +9.8% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 115.58% | Revenue Growth (3Y) | 64.25% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -14.89% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 4.06 M | Net Income (TTM) | -50.22 M |
| ROE | N/A | ROA | -106.34% |
| Gross Margin | 56.67% | Operating Margin | -1260.76% |
| Net Margin | -1238.52% | Free Cash Flow (TTM) | -25.37 M |
| ROIC | -100.79% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.79 |
| Interest Coverage | -469.03 | Asset Turnover | 0.09 |
| Working Capital | 13.73 M | Tangible Book Value | -23.80 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.98 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 24.51 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 12.16 | Fwd Earnings Yield | N/A |
| FCF Yield | -25.52% | ||
| Market Cap | 99.40 M | Enterprise Value | 80.71 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.65 | Revenue / Share | 0.13 |
| FCF / Share | -0.79 | OCF / Share | -0.69 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 78.55% | FCF Conversion | 50.51% |
| SBC-Adj. FCF | -27.32 M | Growth Momentum | 130.47 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.06 M | 1.88 M | 1.50 M | 958,000.0 | 7.73 M |
| Net Income | -50.22 M | -60.66 M | -27.78 M | -72.90 M | -64.10 M |
| EPS (Diluted) | -1.65 | -4.66 | -3.75 | — | — |
| Gross Profit | 2.30 M | 740,000.0 | 413,000.0 | -18,000.0 | 188,000.0 |
| Operating Income | -51.12 M | -61.04 M | -25.14 M | -18.00 M | -74.21 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 15.90 M | 9.84 M | 9.29 M | 7.30 M | 13.63 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 2.20 M | 1.56 M | 1.59 M | 1.50 M | 844,000.0 |
| Interest Expense | -109,000.0 | -84,000.0 | -52,000.0 | -77,000.0 | -209,000.0 |
| Income Tax | 0.0 | 0.0 | — | -9.26 M | -9.26 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 25.76 M | 35.08 M | 74.89 M | 100.09 M | 159.56 M |
| Total Liabilities | 57.22 M | 47.36 M | 49.30 M | 60.50 M | 94.35 M |
| Shareholders' Equity | -31.46 M | -12.27 M | 20.47 M | 34.29 M | 65.22 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 11.58 M | 8.64 M | 9.43 M | 19.99 M | 35.61 M |
| Current Assets | 15.31 M | 11.76 M | 10.70 M | 25.54 M | 39.14 M |
| Current Liabilities | 12.08 M | 7.28 M | 7.19 M | 12.11 M | 14.12 M |
{"event":"ticker_viewed","properties":{"ticker":"IMDX","listing_kind":"stock","pathname":"/stocks/imdx","exchange":"NASDAQ","country":"US"}}